FDA Reduces Regulatory Uncertainty with New Finalized Rule Defining "Biological Product" under BPCIA to Include Insulin and Other "Protein"-Based Products

Published date02 March 2020
Subject MatterPatents,Bright-Line Rule,Biologics,Health Care Providers,BPCIA,Final Rules,Pharmaceutical Industry,FDA,PHSA,Purple Book,Pharmaceutical Patents,Biosimilars
AuthorBrian Sodikoff,Martin S. Masar III, PhD
Law FirmKatten Muchin Rosenman LLP

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT